Previous 10 | Next 10 |
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy PR Newswire STOCKHOLM , Nov. 24, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ...
Calliditas Therapeutics AB (CALT) is expected to report $-0.22 for Q3 2023
Calliditas to present at upcoming investor conferences PR Newswire STOCKHOLM , Nov. 7, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the ...
Calliditas Interim Report January - September 2023 PR Newswire STOCKHOLM , Nov. 7, 2023 /PRNewswire/ -- The Lancet publication of full Phase 3 data set In August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd, published i...
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023 PR Newswire STOCKHOLM , Nov. 6, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("C...
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy PR Newswire STOCKHOLM , Oct. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm...
Calliditas Therapeutics' nomination committee composition for the AGM 2024 PR Newswire STOCKHOLM , Oct. 23, 2023 /PRNewswire/ -- It is hereby announced that Calliditas Therapeutics's major owners have appointed a nomination committee for the AGM 2024. ...
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 PR Newswire STOCKHOLM , Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today a...
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome PR Newswire STOCKHOLM , Oct. 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stoc...
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy PR Newswire STOCKHOLM , Oct. 3, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announced that its partner STADA Arzneimittel ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...
2024-06-10 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to ...